Literature DB >> 3110838

Behavioral teratogenicity of valproic acid: selective effects on behavior after prenatal exposure to rats.

C V Vorhees.   

Abstract

Pregnant Sprague-Dawley rats were treated with 0, 150 or 200 mg/kg valproic acid by gavage (VPA) on days 7-18 of gestation. These doses produced no maternal toxicity, reproductive effects or effects on offspring growth and survival. Maternal plasma VPA peak levels averaged 99 and 134 micrograms/ml 1 h after the last treatment, values approximating human therapeutic levels. VPA offspring tested after weaning exhibited reduced open-field central, but not peripheral, activity and reduced hole-board horizontal, but not vertical, activity. No activity differences were found in a figure-8 test or a preweaning activity test. The VPA offspring also showed lengthened straight channel swimming times, increased swimming maze errors, but only among the females, while producing no differences in maze times. VPA offspring exhibited reduced spontaneous alternation frequency and reduced startle responding to both auditory and tactile (air-puff) stimuli. The effects of VPA were dose dependent in some cases (straight channel swimming and water maze errors), or the effect was seen only in the high-dose group (open-field, hole-board, spontaneous alternation, startle). The conclusion was reached that prenatal VPA is behaviorally teratogenic in rats at relevant maternal blood concentrations and at non-malforming doses.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3110838     DOI: 10.1007/bf00177911

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  23 in total

1.  Valproic acid and spina bifida.

Authors:  T Bjerkedal; A Czeizel; J Goujard; B Kallen; P Mastroiacova; N Nevin; G Oakley; E Robert
Journal:  Lancet       Date:  1982-11-13       Impact factor: 79.321

2.  Possible teratogenicity of valproic acid.

Authors:  M R Gomez
Journal:  J Pediatr       Date:  1981-03       Impact factor: 4.406

3.  The fetal trimethadione syndrome.

Authors:  E H Zackai; W J Mellman; B Neiderer; J W Hanson
Journal:  J Pediatr       Date:  1975-08       Impact factor: 4.406

4.  Risks to the offspring of women treated with hydantoin anticonvulsants, with emphasis on the fetal hydantoin syndrome.

Authors:  J W Hanson; N C Myrianthopoulos; M A Harvey; D W Smith
Journal:  J Pediatr       Date:  1976-10       Impact factor: 4.406

5.  Valproic acid and congenital malformations. A case report.

Authors:  E W Bantz
Journal:  Clin Pediatr (Phila)       Date:  1984-06       Impact factor: 1.168

6.  Maze learning in rats: a comparison of performance in two water mazes in progeny prenatally exposed to different doses of phenytoin.

Authors:  C V Vorhees
Journal:  Neurotoxicol Teratol       Date:  1987 May-Jun       Impact factor: 3.763

7.  Sodium valproate: effects on social behaviour and physical development in the mouse.

Authors:  J B Chapman; M G Cutler
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

8.  Prenatal alcohol exposure alters adult expression of sexually dimorphic behavior in the rat.

Authors:  R F McGivern; A N Clancy; M A Hill; E P Noble
Journal:  Science       Date:  1984-05-25       Impact factor: 47.728

9.  Fetal anticonvulsant syndrome in rats: dose- and period-response relationships of prenatal diphenylhydantoin, trimethadione and phenobarbital exposure on the structural and functional development of the offspring.

Authors:  C V Vorhees
Journal:  J Pharmacol Exp Ther       Date:  1983-11       Impact factor: 4.030

10.  Teratogenesis of calcium valproate in rats.

Authors:  L L Ong; J L Schardein; J A Petrere; R Sakowski; H Jordan; R R Humphrey; J E Fitzgerald; F A de la Iglesia
Journal:  Fundam Appl Toxicol       Date:  1983 Mar-Apr
View more
  15 in total

Review 1.  Developmental neuropathology of environmental agents.

Authors:  Lucio G Costa; Michael Aschner; Annabella Vitalone; Tore Syversen; Offie Porat Soldin
Journal:  Annu Rev Pharmacol Toxicol       Date:  2004       Impact factor: 13.820

Review 2.  The 2017 Dodge Young Investigator Award Lecture: Toward Novel Circuit Therapies for Autism.

Authors:  Audrey C Brumback
Journal:  Pediatr Neurol       Date:  2018-09-06       Impact factor: 3.372

3.  Treatment with MDMA from P11-20 disrupts spatial learning and path integration learning in adolescent rats but only spatial learning in older rats.

Authors:  Matthew R Skelton; Michael T Williams; Charles V Vorhees
Journal:  Psychopharmacology (Berl)       Date:  2006-10-03       Impact factor: 4.530

4.  A new neurobehavioral model of autism in mice: pre- and postnatal exposure to sodium valproate.

Authors:  George C Wagner; Kenneth R Reuhl; Michelle Cheh; Paulette McRae; Alycia K Halladay
Journal:  J Autism Dev Disord       Date:  2006-08

Review 5.  Cognitive/behavioral teratogenetic effects of antiepileptic drugs.

Authors:  Kimford J Meador; Gus Baker; Morris J Cohen; Eija Gaily; Michael Westerveld
Journal:  Epilepsy Behav       Date:  2007-11       Impact factor: 2.937

Review 6.  Cincinnati water maze: A review of the development, methods, and evidence as a test of egocentric learning and memory.

Authors:  Charles V Vorhees; Michael T Williams
Journal:  Neurotoxicol Teratol       Date:  2016-08-18       Impact factor: 3.763

7.  The intense world theory - a unifying theory of the neurobiology of autism.

Authors:  Kamila Markram; Henry Markram
Journal:  Front Hum Neurosci       Date:  2010-12-21       Impact factor: 3.169

8.  Prenatal VPA Exposure and Changes in Sensory Processing by the Superior Colliculus.

Authors:  Georgia Dendrinos; Marie Hemelt; Asaf Keller
Journal:  Front Integr Neurosci       Date:  2011-10-20

9.  The intense world syndrome--an alternative hypothesis for autism.

Authors:  Henry Markram; Tania Rinaldi; Kamila Markram
Journal:  Front Neurosci       Date:  2007-10-15       Impact factor: 4.677

10.  General developmental health in the VPA-rat model of autism.

Authors:  Mônica R Favre; Tania R Barkat; Deborah Lamendola; Georges Khazen; Henry Markram; Kamila Markram
Journal:  Front Behav Neurosci       Date:  2013-07-24       Impact factor: 3.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.